Please let us know if you agree to all of these cookies..
F-star develops novel bispecific antibodies to improve the treatment of serious diseases, with a focus on immuno-oncology.
FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models (2020)
FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity (2020)
CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement (2020)
A Phase 1a/1b Dose-escalation Study of Intravenously Administered SB 11285 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors (2020)
Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics (2019)
Two-faced Fcab prevents polymerization with VEGF and reveals thermodynamics and the 2.15 Å crystal structure of the complex (2017)
A HER2-specific modified Fc fragment (Fcab) induces anti-tumour effects through degradation of HER2 and apoptosis. Molecular Therapy (2015).